DR info

臨床試験数 : 45 / 薬物数 : 21 - (DrugBank : 10) / 標的遺伝子数 : 3 - 標的パスウェイ数 : 5

薬物ごとの開発者（Primary Sponsor）、臨床試験情報（抜粋）です。

A4250
   ALBIREO AB
      2021   Phase 3   EUCTR2020-004011-28-IT   Australia;Belgium;Canada;Denmark;France;Germany;Italy;Netherlands;Poland;United Kingdom;United States;
   Albireo
      2013   Phase 1   NCT02963077   -
   Albireo AB
      2022   Phase 3   EUCTR2021-000996-36-NL   Belgium;Canada;France;Germany;Israel;Italy;Malaysia;Netherlands;New Zealand;Poland;Turkey;United Kingdom;United States;
      2021   Phase 3   EUCTR2020-004011-28-NL   Australia;Belgium;Canada;Denmark;France;Germany;Italy;Netherlands;Poland;United Kingdom;United States;
      2021   Phase 3   EUCTR2020-004011-28-FR   Australia;Belgium;Canada;Denmark;France;Germany;Italy;Netherlands;Poland;United Kingdom;United States;
      2021   Phase 3   EUCTR2020-004011-28-DE   Belgium;Canada;France;Germany;Israel;Italy;Malaysia;Netherlands;New Zealand;Poland;Turkey;United Kingdom;United States;
      -   Phase 3   EUCTR2021-000996-36-PL   Belgium;Canada;France;Germany;Israel;Italy;Malaysia;Netherlands;New Zealand;Poland;Turkey;United Kingdom;United States;
      -   Phase 3   EUCTR2021-000996-36-FR   Belgium;Canada;France;Germany;Israel;Italy;Malaysia;Netherlands;New Zealand;Poland;Turkey;United Kingdom;United States;
      -   Phase 3   EUCTR2021-000996-36-DE   Belgium;Canada;France;Germany;Israel;Italy;Malaysia;Netherlands;New Zealand;Poland;Turkey;United Kingdom;United States;
      -   Phase 3   EUCTR2021-000996-36-BE   Belgium;Canada;France;Germany;Israel;Italy;Malaysia;Netherlands;New Zealand;Poland;Turkey;United Kingdom;United States;
      -   Phase 3   EUCTR2020-004011-28-PL   Australia;Belgium;Canada;Denmark;France;Germany;Italy;Netherlands;Poland;United Kingdom;United States;
      -   Phase 3   EUCTR2020-004011-28-BE   Australia;Belgium;Canada;Denmark;France;Germany;Israel;Italy;Malaysia;Netherlands;New Zealand;Poland;Turkey;United Kingdom;United States;
A4250-015
   ALBIREO AB
      2021   Phase 3   EUCTR2021-000996-36-IT   Belgium;Canada;France;Germany;Israel;Italy;Malaysia;Netherlands;New Zealand;Poland;Turkey;United Kingdom;United States;
CRC (A3384)
   Albireo
      2013   Phase 1   NCT02963077   -
Eicosapentaenoic acid
   Sumida Wataru
      2016   -   JPRN-jRCTs041180088   Japan;
LUM001
   Lumena Pharmaceuticals Inc
      2014   Phase 2   EUCTR2013-005373-43-ES   Australia;Belgium;Canada;France;Poland;Spain;United Kingdom;
      -   Phase 2   EUCTR2013-005373-43-FR   Australia;Belgium;Canada;France;Poland;Spain;United Kingdom;
   Lumena Pharmaceuticals LLC
      2015   Phase 2   EUCTR2013-005373-43-BE   Australia;Belgium;France;Poland;Spain;United Kingdom;
   Lumena Pharmaceuticals, Inc.
      2013   -   EUCTR2012-005346-38-GB   United Kingdom;
   Mirum Pharmaceuticals, Inc.
      2015   Phase 2   EUCTR2013-005373-43-GB   Australia;Belgium;France;Poland;Spain;United Kingdom;
      2014   Phase 2   NCT02160782   Australia;Belgium;Canada;France;Germany;Poland;Spain;United Kingdom;
      2014   Phase 2   NCT02057692   Canada;United States;
      2013   Phase 2   NCT01903460   United Kingdom;
      2013   Phase 2   EUCTR2013-003832-54-GB   United Kingdom;
   Mirum Pharmaceuticals,Inc.
      -   Phase 2   EUCTR2013-005373-43-PL   Australia;Belgium;France;Poland;Spain;United Kingdom;
   Shire Human Genetic Therapies Inc
      2015   Phase 2   EUCTR2015-000906-20-GB   Australia;Canada;United Kingdom;United States;
LUM001 (Maralixibat)
   Mirum Pharmaceuticals, Inc.
      2015   Phase 2   NCT02117713   Canada;United States;
      2013   Phase 2   NCT02047318   United Kingdom;
MARALIXIBAT CHLORIDE
   Mirum Pharmaceuticals Inc
      2021   Phase 2   EUCTR2020-004628-40-FR   Belgium;France;Poland;United Kingdom;
      2021   Phase 2   EUCTR2020-004628-40-BE   Belgium;France;Poland;United Kingdom;
      -   Phase 2   EUCTR2020-004628-40-PL   Belgium;France;Poland;United Kingdom;
   Mirum Pharmaceuticals Inc.
      2020   Phase 2   EUCTR2019-002755-42-GB   Australia;Belgium;Canada;France;Poland;Spain;United Kingdom;United States;
      2020   Phase 2   EUCTR2019-002755-42-FR   Australia;Belgium;Canada;France;Poland;Spain;United Kingdom;United States;
      2020   Phase 2   EUCTR2019-002755-42-ES   Australia;Belgium;Canada;France;Poland;Spain;United Kingdom;United States;
      -   Phase 2   EUCTR2019-002755-42-PL   Australia;Belgium;Canada;France;Poland;Spain;United Kingdom;United States;
      -   Phase 2   EUCTR2019-002755-42-BE   Australia;Belgium;Canada;France;Poland;Spain;United Kingdom;United States;
Magnesium gluconate
   National Center for Research Resources (NCRR)
      2000   -   NCT00007033   United States;
Magnesium sulfate
   National Center for Research Resources (NCRR)
      2000   -   NCT00007033   United States;
Maralixibat
   Mirum Pharmaceuticals, Inc.
      2021   Phase 2   NCT04729751   Belgium;France;Poland;United Kingdom;United States;
      2020   -   NCT04530994   United States;
Maralixibat (formely SHP625 or LUM001)
   Mirum Pharmaceuticals Inc
      2021   Phase 2   EUCTR2020-004628-40-FR   Belgium;France;Poland;United Kingdom;
      2021   Phase 2   EUCTR2020-004628-40-BE   Belgium;France;Poland;United Kingdom;
      -   Phase 2   EUCTR2020-004628-40-PL   Belgium;France;Poland;United Kingdom;
   Mirum Pharmaceuticals Inc.
      2020   Phase 2   EUCTR2019-002755-42-GB   Australia;Belgium;Canada;France;Poland;Spain;United Kingdom;United States;
      2020   Phase 2   EUCTR2019-002755-42-FR   Australia;Belgium;Canada;France;Poland;Spain;United Kingdom;United States;
      2020   Phase 2   EUCTR2019-002755-42-ES   Australia;Belgium;Canada;France;Poland;Spain;United Kingdom;United States;
      -   Phase 2   EUCTR2019-002755-42-PL   Australia;Belgium;Canada;France;Poland;Spain;United Kingdom;United States;
      -   Phase 2   EUCTR2019-002755-42-BE   Australia;Belgium;Canada;France;Poland;Spain;United Kingdom;United States;
Maralixibat chloride
   Mirum Pharmaceuticals, Inc.
      2015   Phase 2   EUCTR2013-005373-43-GB   Australia;Belgium;France;Poland;Spain;United Kingdom;
      2013   Phase 2   EUCTR2013-003832-54-GB   United Kingdom;
   Mirum Pharmaceuticals,Inc.
      -   Phase 2   EUCTR2013-005373-43-PL   Australia;Belgium;France;Poland;Spain;United Kingdom;
Odevixibat
   ALBIREO AB
      2021   Phase 3   EUCTR2021-000996-36-IT   Belgium;Canada;France;Germany;Israel;Italy;Malaysia;Netherlands;New Zealand;Poland;Turkey;United Kingdom;United States;
      2021   Phase 3   EUCTR2020-004011-28-IT   Australia;Belgium;Canada;Denmark;France;Germany;Italy;Netherlands;Poland;United Kingdom;United States;
   Albireo
      2021   Phase 3   NCT05035030   France;Poland;United Kingdom;United States;
      2021   Phase 3   NCT04674761   Belgium;Canada;France;Germany;Israel;Italy;Malaysia;Netherlands;New Zealand;Poland;Turkey;United Kingdom;United States;
   Albireo AB
      2022   Phase 3   EUCTR2021-000996-36-NL   Belgium;Canada;France;Germany;Israel;Italy;Malaysia;Netherlands;New Zealand;Poland;Turkey;United Kingdom;United States;
      2021   Phase 3   EUCTR2020-004011-28-NL   Australia;Belgium;Canada;Denmark;France;Germany;Italy;Netherlands;Poland;United Kingdom;United States;
      2021   Phase 3   EUCTR2020-004011-28-FR   Australia;Belgium;Canada;Denmark;France;Germany;Italy;Netherlands;Poland;United Kingdom;United States;
      2021   Phase 3   EUCTR2020-004011-28-DE   Belgium;Canada;France;Germany;Israel;Italy;Malaysia;Netherlands;New Zealand;Poland;Turkey;United Kingdom;United States;
      -   Phase 3   EUCTR2021-000996-36-PL   Belgium;Canada;France;Germany;Israel;Italy;Malaysia;Netherlands;New Zealand;Poland;Turkey;United Kingdom;United States;
      -   Phase 3   EUCTR2021-000996-36-FR   Belgium;Canada;France;Germany;Israel;Italy;Malaysia;Netherlands;New Zealand;Poland;Turkey;United Kingdom;United States;
      -   Phase 3   EUCTR2021-000996-36-DE   Belgium;Canada;France;Germany;Israel;Italy;Malaysia;Netherlands;New Zealand;Poland;Turkey;United Kingdom;United States;
      -   Phase 3   EUCTR2021-000996-36-BE   Belgium;Canada;France;Germany;Israel;Italy;Malaysia;Netherlands;New Zealand;Poland;Turkey;United Kingdom;United States;
      -   Phase 3   EUCTR2020-004011-28-PL   Australia;Belgium;Canada;Denmark;France;Germany;Italy;Netherlands;Poland;United Kingdom;United States;
      -   Phase 3   EUCTR2020-004011-28-BE   Australia;Belgium;Canada;Denmark;France;Germany;Israel;Italy;Malaysia;Netherlands;New Zealand;Poland;Turkey;United Kingdom;United States;
Phenylbutyrate
   Juntendo University
      2014   -   JPRN-UMIN000012782   Japan;
   Saiseikai Yokohama City Tobu Hospital
      2010   -   JPRN-UMIN000003802   Japan;
Questran
   Albireo
      2013   Phase 1   NCT02963077   -
[14C]-A4250 capsule
   Albireo
      2017   Phase 1   NCT03082937   United Kingdom;